X-116172778-T-C
Position:
Variant summary
Our verdict is Benign. Variant got -21 ACMG points: 0P and 21B. BP4_StrongBP6_Very_StrongBP7BS1BS2
The NM_000686.5(AGTR2):āc.498T>Cā(p.Leu166=) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00078 in 1,209,232 control chromosomes in the GnomAD database, including 9 homozygotes. There are 241 hemizygotes in GnomAD. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (ā ā ).
Frequency
Genomes: š 0.0039 ( 6 hom., 99 hem., cov: 23)
Exomes š: 0.00046 ( 3 hom. 142 hem. )
Consequence
AGTR2
NM_000686.5 synonymous
NM_000686.5 synonymous
Scores
2
Clinical Significance
Conservation
PhyloP100: -0.844
Genes affected
AGTR2 (HGNC:338): (angiotensin II receptor type 2) The protein encoded by this gene belongs to the G-protein coupled receptor 1 family, and functions as a receptor for angiotensin II. It is an intergral membrane protein that is highly expressed in fetus and in neonates, but scantily in adult tissues, except brain, adrenal medulla, and atretic ovary. This receptor has been shown to mediate programmed cell death and this apoptotic function may play an important role in developmental biology and pathophysiology. Mutations in this gene are been associated with X-linked cognitive disability. Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and SARS-CoV-2 infection results in down-regulation of angiotensin converting enzyme-2 (ACE2) receptors, the effects of which, triggers serious inflammatory lesions in the tissues involved, primarily in the lungs. The inflammatory reaction appears to be mediated by angiotensin II derivatives, including the angiotensin AT2 receptor which has been found to be upregulated in bronchoalveolar lavage samples from Coronavirus disease 2019 (COVID19) patients. [provided by RefSeq, Jul 2020]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -21 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.81).
BP6
Variant X-116172778-T-C is Benign according to our data. Variant chrX-116172778-T-C is described in ClinVar as [Benign]. Clinvar id is 590238.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BP7
Synonymous conserved (PhyloP=-0.844 with no splicing effect.
BS1
Variant frequency is greater than expected in population afr. gnomad4_exome allele frequency = 0.000464 (509/1097690) while in subpopulation AFR AF= 0.0164 (432/26379). AF 95% confidence interval is 0.0151. There are 3 homozygotes in gnomad4_exome. There are 142 alleles in male gnomad4_exome subpopulation. Median coverage is 31. This position pass quality control queck.
BS2
High Homozygotes in GnomAd4 at 6 XL gene
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
AGTR2 | NM_000686.5 | c.498T>C | p.Leu166= | synonymous_variant | 3/3 | ENST00000371906.5 | |
AGTR2 | NM_001385624.1 | c.498T>C | p.Leu166= | synonymous_variant | 2/2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
AGTR2 | ENST00000371906.5 | c.498T>C | p.Leu166= | synonymous_variant | 3/3 | 1 | NM_000686.5 | P1 | |
AGTR2 | ENST00000681852.1 | c.498T>C | p.Leu166= | synonymous_variant | 2/2 | P1 | |||
AGTR2 | ENST00000680409.1 | n.966T>C | non_coding_transcript_exon_variant | 1/1 |
Frequencies
GnomAD3 genomes AF: 0.00388 AC: 433AN: 111486Hom.: 6 Cov.: 23 AF XY: 0.00291 AC XY: 98AN XY: 33702
GnomAD3 genomes
AF:
AC:
433
AN:
111486
Hom.:
Cov.:
23
AF XY:
AC XY:
98
AN XY:
33702
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.00148 AC: 271AN: 183321Hom.: 3 AF XY: 0.000826 AC XY: 56AN XY: 67821
GnomAD3 exomes
AF:
AC:
271
AN:
183321
Hom.:
AF XY:
AC XY:
56
AN XY:
67821
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000464 AC: 509AN: 1097690Hom.: 3 Cov.: 31 AF XY: 0.000391 AC XY: 142AN XY: 363120
GnomAD4 exome
AF:
AC:
509
AN:
1097690
Hom.:
Cov.:
31
AF XY:
AC XY:
142
AN XY:
363120
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.00389 AC: 434AN: 111542Hom.: 6 Cov.: 23 AF XY: 0.00293 AC XY: 99AN XY: 33768
GnomAD4 genome
AF:
AC:
434
AN:
111542
Hom.:
Cov.:
23
AF XY:
AC XY:
99
AN XY:
33768
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ClinVar
Significance: Benign
Submissions summary: Benign:2
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not specified Benign:1
Benign, criteria provided, single submitter | clinical testing | Ambry Genetics | May 06, 2016 | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
not provided Benign:1
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jul 31, 2018 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at